Compare BridgeBio Pharma Inc (BBIO) vs Allbirds Inc (BIRD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Allbirds Inc — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while Allbirds Inc trades at $3 (market cap $25.89M). The key difference: BridgeBio Pharma Inc is far larger — about 635.8× Allbirds Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | BIRD | |
|---|---|---|
Market Cap | $16.46B | $25.89M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $16.99 |
52-Week Low | $44.81 | $2.39 |
Enterprise Value | $18.02B | $44.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BIRD (Smartbird) trades at $3.00, down 4.15% today, amid a complete business pivot from footwear to AI infrastructure. The stock shows a bearish technical trend with all moving averages signaling sell, while oscillators suggest potential oversold conditions. Fundamentally, the company reports declining revenue ($152M in 2025) and persistent losses (-$77M net income), though it maintains a low P/S ratio of 0.17. Recent news highlights the strategic shift, including a rebrand to Smartbird and appointment of a new CEO from Amazon Web Services (Reuters, June 17, 2026).
The outlook is highly speculative, driven by the unproven AI strategy rather than current fundamentals. Investment opportunity lies in potential AI sector growth, but risks include execution challenges, cash burn (-$40M net cash flow in 2025), and intense competition. Analysts are cautious with 79% hold ratings, reflecting uncertainty about the pivot's success. Shareholders face volatility as the company transitions from a tangible product business to technology infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
